The once-daily treatment combines the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. FDA Approvals …read more April 30, 2015Post navigationPreviousPrevious post:Experts Continue to Scale Back Cervical Cancer ScreeningNextNext post:Genital-only screening misses many cases of gonorrhea and chlamydia in women
Nice posts! 🙂
___
Sanny